Sign Up to like & get
recommendations!
0
Published in 2020 at "International journal of antimicrobial agents"
DOI: 10.1016/j.ijantimicag.2020.106228
Abstract: The main goal of the present study was to investigate the "in vitro" activity of taniborbactam (VNRX-5133), a novel broad-spectrum bicyclic boronate, against NDM-1 and Q119E, Q119K, Q119C, Q119F, Q119V and Q119Y NDM-1 variants which…
read more here.
Keywords:
taniborbactam;
vitro activity;
activity taniborbactam;
activity cefepime ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2022 at "Antimicrobial Agents and Chemotherapy"
DOI: 10.1128/aac.01281-22
Abstract: Taniborbactam is a novel cyclic boronate β-lactamase inhibitor in clinical development in combination with cefepime. We assessed the in vitro activity of cefepime-taniborbactam and comparators against a 2018–2020 collection of Enterobacterales (n = 13,731) and Pseudomonas aeruginosa…
read more here.
Keywords:
activity cefepime;
vitro activity;
taniborbactam;
cefepime taniborbactam ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2022 at "Antimicrobial Agents and Chemotherapy"
DOI: 10.1128/aac.02161-21
Abstract: Novel β-lactam–β-lactamase inhibitor combinations currently approved for clinical use are poorly active against metallo-β-lactamase (MBL)-producing strains. We evaluated the in vitro activity of cefepime-taniborbactam (FTB [formerly cefepime–VNRX-5133]) and comparator agents against carbapenemase-producing Enterobacterales (n = 247) and…
read more here.
Keywords:
vitro activity;
cefepime taniborbactam;
producing enterobacterales;
activity cefepime ... See more keywords